Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center
Current Oncology · 2025
DOI: 10.3390/curroncol32050285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Mathias Castonguay und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, QC H1T 2M4…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lymphoma, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Famille Casser Fund, Famille Cassar Fund of Université de Montréal.
Abstract (Originalsprache)
Background
Allogeneic hematopoietic cell transplant (alloHCT) is a curative option for relapsed/refractory B-cell lymphomas (BCLs), but its role in the evolving field of cellular therapy is increasingly unclear as recent advances in transplant procedures have improved outcomes.
Methods
This retrospective, single-center study included 55 BCL patients (large B-cell lymphoma—LBCL; indolent BCL; and mantle cell lymphoma—MCL) treated with alloHCT from 2015 to 2023 at Hôpital Maisonneuve-Rosemont. Primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints included NRM and GVHD incidence.
Results
A total of 55 patients were included (25 LBCLs, 16 indolent BCLs, 14 MCLs), and 76% of LBCLs were of indolent origin (Richter transformation, transformed follicular lymphoma). After a median follow-up of 6.1, 5.8 and 2.4 years for LBCLs, indolent BCLs and MCLs, their 5-year PFS and OS were 57.2% (IC 95%: 34.2–74.7) and 62.8% (IC 95%: 37.9–80.0), 81.2% (IC 95%: 52.5–93.5) and 93.8% (IC 95%: 63.2–99.1), and 39.0% (IC 95%: 14.3–63.3) and 68.1% (IC 95%: 35.4–86.8), respectively. The 5-year NRM was 16.9% (IC 95%: 8.2–28.3) with a relapse incidence of 23.4%. Overall/grade 3–4 acute GVHD occurred in 43.6% and 18.1% of patients. At 3 years, overall/moderate or severe chronic GVHD incidence was 49% and 34.5%.
Conclusions
AlloHCT remains a potentially curative option and should be considered for fit patients with chemosensitive FL or LBCLs of indolent origin and a low comorbidity index.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, QC H1T 2M4, Canada.
ORCID-Profile: Mathias Castonguay, Jean Roy, Jean-Sébastien Claveau, Sylvie Lachance, Jean-Sébastien Delisle, Imran Ahmad, Denis-Claude Roy, Olivier Veilleux
Förderung
- Famille Casser Fund
- Famille Cassar Fund of Université de Montréal
Zitieren
APA
Castonguay, M., Roy, J., Claveau, J. S., Lachance, S., Delisle, J. S., Kiss, T., Cohen, S., Fleury, I., Mollica, L., Ahmad, I., Bambace, N., Bernard, L., Roy, D. C., Sauvageau, G., & Veilleux, O. (2025). Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center. Current Oncology. https://doi.org/10.3390/curroncol32050285
Vancouver
Castonguay M, Roy J, Claveau JS, Lachance S, Delisle JS, Kiss T, et al. Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center. Current Oncology. 2025. doi:10.3390/curroncol32050285
BibTeX
@article{Castonguay2025,
author = {Castonguay, Mathias and Roy, Jean and Claveau, Jean-Sébastien and Lachance, Sylvie and Delisle, Jean-Sébastien and Kiss, Thomas and Cohen, Sandra and Fleury, Isabelle and Mollica, Luigina and Ahmad, Imran and Bambace, Nadia and Bernard, Léa and Roy, Denis-Claude and Sauvageau, Guy and Veilleux, Olivier},
title = {Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32050285}
}
EUVIMED